Literature DB >> 16262593

Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study.

Slavica K Katusic1, William J Barbaresi, Robert C Colligan, Amy L Weaver, Cynthia L Leibson, Steven J Jacobsen.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the association between stimulant treatment and the risk for substance abuse among young adults with a childhood diagnosis of attention- deficit/hyperactivity disorder (ADHD).
METHODS: Subjects included 295 research-identified ADHD incidence cases treated with psychostimulant medication and 84 ADHD cases not treated with psychostimulants. These subjects are from a 1976-1982 population-based birth cohort, retrospectively, followed from birth until emigration, death, or last follow-up (mean = 17.2 years of follow-up). Medical and school records were reviewed for documented substance abuse and psychostimulant treatment. The association was evaluated using logistic regression models.
RESULTS: Socioeconomic characteristics at birth, and comorbidities, were similar between treated and untreated ADHD cases. Sixty (20.3%) of treated ADHD cases had documented substance abuse compared to 23 (27.4%) of cases not treated (OR = 0.7; 95% CI = 0.4-1.2). Among treated ADHD boys, 21.8% had substance abuse compared to 36.4% not-treated ADHD boys (OR = 0.5; 95% CI = 0.3-0.9). Among treated ADHD girls, 15.2% had substance abuse compared to 10.3% not-treated ADHD girls (OR = 1.5; 95% CI = 0.4-6.1).
CONCLUSION: While these results cannot demonstrate cause and effect, our findings indicate that psychostimulant treatment of childhood ADHD is associated with reduced risk for later substance abuse among boys with ADHD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262593     DOI: 10.1089/cap.2005.15.764

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  46 in total

1.  Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder.

Authors:  M Feldman; S Bélanger
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

2.  Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder.

Authors:  Daniel J Coletti; Elizabeth Pappadopulos; Nikki J Katsiotas; Alison Berest; Peter S Jensen; Vivian Kafantaris
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-04-26       Impact factor: 2.576

3.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

4.  Peak ages of risk for starting nonmedical use of prescription stimulants.

Authors:  E A Austic; E A Austic Formerly E A Meier
Journal:  Drug Alcohol Depend       Date:  2015-04-09       Impact factor: 4.492

5.  Adolescents' Prescription Stimulant Use and Adult Functional Outcomes: A National Prospective Study.

Authors:  Sean Esteban McCabe; Philip Veliz; Timothy E Wilens; John E Schulenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-12-25       Impact factor: 8.829

6.  ADHD, Conduct Disorder, Substance Use Disorder, and Nonprescription Stimulant Use.

Authors:  Judith S Brook; Elinor B Balka; Chenshu Zhang; David W Brook
Journal:  J Atten Disord       Date:  2014-04-28       Impact factor: 3.256

7.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

Review 8.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 9.  Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms.

Authors:  Thomas J Spencer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapy.

Authors:  Alexandra Philipsen; Bernd Hesslinger; Ludger Tebartz van Elst
Journal:  Dtsch Arztebl Int       Date:  2008-04-25       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.